1-4 of 4
Scott J Keating
Close
Sort by
Journal Articles

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana
Journal: Blood
Blood (2023) 142 (Supplement 1): 2340.
https://doi.org/10.1182/blood-2023-178017
Published: 2023
Journal Articles

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana
Journal: Blood
Blood (2023) 142 (Supplement 1): 3717.
https://doi.org/10.1182/blood-2023-177989
Published: 2023
Journal Articles

Examination of Disparities in Access to Chimeric Antigen Receptor (CAR) T Cell Therapies in Medicare Patients (Pts) with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Who Had Failed at Least 2 Prior Lines of Therapy (LOT)

Ashley Saunders, Sushmitha Inguva, Scott J Keating, Viktor Chirikov
Journal: Blood
Blood (2022) 140 (Supplement 1): 10921–10923.
https://doi.org/10.1182/blood-2022-160313
Published: 2022
Journal Articles

Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Parker, Fei Fei Liu, Kristen Deger, Conrado Franco-Villalobos, Irina Proskorovsky, Scott J Keating, Sonja Sorensen, Emily Dorman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3003.
https://doi.org/10.1182/blood-2021-150755
Published: 2021